Company news

Tenax Therapeutics, Inc. news in 2022

Tenax Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

September 14, 2022

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

May 22, 2022

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

May 17, 2022

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

March 30, 2022

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

March 29, 2022

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

January 30, 2022

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

January 11, 2022

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

January 3, 2022

Decks in 2022